Olema Pharmaceuticals annual free cash flow
2020
2021
2022
2024
Olema Pharmaceuticals reported −$104.5M in free cash flow for fiscal 2024.
View full Olema Pharmaceuticals company overview| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$104.5M | — | — | — |
| 2022 | 2022-12-31 | −$82.4M | −$30.2M | — | — |
| 2021 | 2021-12-31 | −$52.3M | −$32.3M | — | — |
| 2020 | 2020-12-31 | −$19.9M | — | — | — |
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | −$34.5M | −$7.5M | — | — |
| Q4 2024 | 2024-12-31 | −$26.3M | — | — | — |
| Q3 2024 | 2024-09-30 | −$27.0M | — | — | — |
| Q2 2024 | 2024-06-30 | −$27.6M | — | — | — |
| Q1 2024 | 2024-03-31 | −$23.6M | — | — | — |
| Q4 2022 | 2022-12-31 | −$19.9M | −$582,000 | — | — |
| Q3 2022 | 2022-09-30 | −$18.1M | −$5.9M | — | — |
| Q2 2022 | 2022-06-30 | −$26.5M | −$17.2M | — | — |
| Q1 2022 | 2022-03-31 | −$17.9M | −$6.4M | — | — |
| Q4 2021 | 2021-12-31 | −$19.3M | −$10.2M | — | — |
| Q3 2021 | 2021-09-30 | −$12.2M | −$4.6M | — | — |
| Q2 2021 | 2021-06-30 | −$9.3M | −$8.1M | — | — |
| Q1 2021 | 2021-03-31 | −$11.5M | −$9.4M | — | — |
| Q4 2020 | 2020-12-31 | −$9.1M | — | — | — |
| Q3 2020 | 2020-09-30 | −$7.5M | — | — | — |
| Q2 2020 | 2020-06-30 | −$1.2M | — | — | — |
| Q1 2020 | 2020-03-31 | −$2.1M | — | — | — |
Olema Pharmaceuticals's latest reported quarter, Q3 2025, generated −$34.5M in free cash flow, a decrease of $7.5M year over year.
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Olema Pharmaceuticals source filings ↗